Table 4 Diagnostic testing during the 5 years prior to ATTRv amyloidosis diagnosis
From: The patient journey toward a diagnosis of hereditary transthyretin (ATTRv) amyloidosis
Newly diagnosed ATTRv Amyloidosis Patients N = 141 | Matched controlsa N = 423 | p value | Newly diagnosed ATTRv Amyloidosis Patients N = 141 | Matched controlsa N = 423 | p value | Newly diagnosed ATTRv Amyloidosis Patients N = 141 | Matched controlsa N = 423 | p value | |
|---|---|---|---|---|---|---|---|---|---|
Pyrophosphate imaging (PYP) | Cardiac magnetic resonance imaging (MRI) | Echocardiogram | |||||||
N (%) | 3 (2.1) | 0 (0.0) | 0.003 | 10 (7.1) | 1 (0.2) | < 0.001 | 80 (56.7) | 114 (27.0) | < 0.001 |
First evidence occurred | 138 (97.9) | 423 (100.0) | 0.003 | 131 (92.9) | 422 (99.8) | < 0.001 | 61 (43.3) | 309 (73.0) | < 0.001 |
No evidence | |||||||||
Pre Y1 | 3 (2.1) | 0 (0) | 6 (4.3) | 1 (0.2) | 12 (8.5) | 19 (4.5) | |||
Pre Y2 | 0 (0) | 0 (0) | 1 (0.7) | 0 (0) | 11 (7.8) | 14 (3.3) | |||
Pre Y3 | 0 (0) | 0 (0) | 1 (0.7) | 0 (0) | 11 (7.8) | 19 (4.5) | |||
Pre Y4 | 0 (0) | 0 (0) | 2 (1.4) | 0 (0) | 19 (13.5) | 21 (5.0) | |||
Pre Y5 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 27 (19.1) | 41 (9.7) | |||
Blood/urine testing | p value | Tissue biopsy or genetic testingb | p value | ||||||
|---|---|---|---|---|---|---|---|---|---|
N (%) | 49 (34.8) | 40 (9.5) | < 0.001 | 49 (34.8) | 88 (20.8) | < 0.001 | |||
First evidence occurred | < 0.001 | 0.003 | |||||||
No evidence | 92 (65.2) | 383 (90.5) | 92 (65.2) | 335 (79.2) | |||||
Pre Y1 | 14 (9.9) | 13 (3.1) | 11 (7.8) | 14 (3.3) | |||||
Pre Y2 | 7 (5.0) | 6 (1.4) | 7 (5.0) | 12 (2.8) | |||||
Pre Y3 | 10 (7.1) | 7 (1.7) | 13 (9.2) | 14 (3.3) | |||||
Pre Y4 | 10 (7.1) | 7 (1.7) | 10 (7.1) | 21 (5.0) | |||||
Pre Y5 | 8 (5.7) | 7 (1.7) | 8 (5.7) | 27 (6.4) | |||||